Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical leader advancing epicutaneous immunotherapy (EPIT) through its innovative Viaskin platform, targeting food allergies with non-invasive precision. This page aggregates all essential updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Investors and stakeholders gain centralized access to critical developments including phase trial results, FDA/EMA interactions, and partnership announcements. Each update is curated to provide actionable insights into DBVT’s pioneering work in allergy treatment while maintaining rigorous scientific accuracy.
Key coverage areas include Viaskin efficacy data, patent developments, and manufacturing scalability updates. The resource is designed to help users track the company’s progress from clinical research to potential commercialization without requiring cross-platform monitoring.
Bookmark this page for streamlined tracking of DBV Technologies’ advancements in redefining food allergy management through its unique skin-based immunotherapy approach.
DBV Technologies announced a change in the ADS ratio from one ADS for one-half of an ordinary share to one ADS for one ordinary share, effective June 7, 2024. This change will act as a one-for-two reverse ADS split, aiming to regain compliance with Nasdaq's minimum bid price requirement. Registered ADS holders must surrender their certificated ADSs for cancellation and will receive new ADSs in exchange. Uncertificated ADSs will be automatically exchanged. No fractional new ADSs will be issued; instead, they will be aggregated and sold, with proceeds distributed to ADS holders. This change will not affect DBV's underlying ordinary shares.
DBV Technologies, a clinical-stage biopharmaceutical company, announced its participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress from May 31 to June 3, 2024, in Valencia, Spain. The company will present data on accidental peanut consumption from its EPITOPE Phase 3 study and its ongoing open-label extension study in peanut-allergic toddlers aged 1 to 3 years.
The presentation by Dr. Nicolette Arends will describe the data collection. DBV will also host a symposium moderated by Dr. Stefania Arasi and Dr. Philippe Eigenmann, featuring lectures on the potential clinical applications of epicutaneous immunotherapy. Additionally, DBV will have an exhibit booth to showcase their ongoing clinical trials in peanut-allergic children.
CEO Daniel Tassé emphasized the importance of long-term safety and clinical data, while Chief Medical Officer Pharis Mohideen highlighted the real-world benefits of Viaskin Peanut in reducing allergic reactions over time.
DBV Technologies, a clinical-stage biopharmaceutical company, announced plans to change its American Depositary Shares (ADS) ratio from one ADS to half an ordinary share, to one ADS to one ordinary share. This change, effective June 3, 2024, will act like a one-for-two reverse ADS split, helping the company meet the Nasdaq minimum bid price requirement. Registered ADS holders must surrender their ADSs for cancellation, receiving one new ADS for every two surrendered. Uncertificated ADS holders will see an automatic exchange. The ticker symbol 'DBVT' remains unchanged, and no new ordinary shares will be issued or canceled.
DBV Technologies, a clinical-stage biopharmaceutical company, announced that all resolutions proposed at its 2024 Combined General Meeting were approved by shareholders. The meeting, chaired by Michel de Rosen, took place on May 16, 2024, in Châtillon, France. The resolutions cover various strategic and operational plans aimed at advancing DBV's focus on treatments for food allergies and immunologic conditions with significant unmet needs. Detailed results are available on the company's website.
DBV Technologies, a biopharmaceutical company, will participate in two investor conferences in May 2024. The CEO will present at the Citizens JMP Life Sciences Conference on May 13 and the H.C. Wainwright BioConnect Conference on May 20. The presentations will be available via live webcast on the company's website.
DBV Technologies, a biopharmaceutical company, released its First Quarter 2024 Financial Results and Business Update. The company reported a cash balance of $101.5 million, with VITESSE Phase 3 study enrollment progressing well. Robert Pietrusko was appointed Chief Regulatory Officer. Financially, the company saw a net cash decrease due to operating activities, and faces uncertainties in sustaining operations.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
